Biotechnology · Langhorne, Pennsylvania, United States
$6.28
-1.80% (-$0.11)2026-07-09
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$2.2M, 13 sales vs 6 buys)
Net Income-$37.3M
EPS$-0.15
Market Cap$1.3B
Price Performance
Historical data including institutional events
Company Profile
M
Matthew Pauls
CEO & Executive Director
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
The companyâs lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
